 | • レポートコード：MRC2102QY0167 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の副腎白質ジストロフィー治療薬市場について種類別（ホルモン補充療法、移植、その他）、用途別（小児脳ALD、副腎白質神経障害（AMN）、アディソンのみ、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・副腎白質ジストロフィー治療薬市場の概要 ・世界の主要地域別副腎白質ジストロフィー治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の副腎白質ジストロフィー治療薬市場規模2015-2026：種類別（ホルモン補充療法、移植、その他） ・世界の副腎白質ジストロフィー治療薬市場規模2015-2026：用途別（小児脳ALD、副腎白質神経障害（AMN）、アディソンのみ、その他） ・副腎白質ジストロフィー治療薬の米国市場規模2015-2020 ・副腎白質ジストロフィー治療薬のヨーロッパ市場規模2015-2020 ・副腎白質ジストロフィー治療薬の中国市場規模2015-2020 ・副腎白質ジストロフィー治療薬の日本市場規模2015-2020 ・副腎白質ジストロフィー治療薬の東南アジア市場規模2015-2020 ・副腎白質ジストロフィー治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・副腎白質ジストロフィー治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・副腎白質ジストロフィー治療薬の市場動向・機会・課題 ・調査の結論 |
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
Market Analysis and Insights: Global Adrenoleukodystrophy Drugs Market
The global Adrenoleukodystrophy Drugs market size is projected to reach US$ 706.4 million by 2026, from US$ 291.5 million in 2020, at a CAGR of 15.9% during 2021-2026.
Global Adrenoleukodystrophy Drugs Scope and Market Size
The global Adrenoleukodystrophy Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adrenoleukodystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Adrenoleukodystrophy Drugs market is segmented into
Hormone Replacement
Transplant
Others
Segment by Application, the Adrenoleukodystrophy Drugs market is segmented into
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
The Adrenoleukodystrophy Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Adrenoleukodystrophy Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Adrenoleukodystrophy Drugs Market Share Analysis
Adrenoleukodystrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Adrenoleukodystrophy Drugs business, the date to enter into the Adrenoleukodystrophy Drugs market, Adrenoleukodystrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
1 Adrenoleukodystrophy Drugs Market Overview
1.1 Adrenoleukodystrophy Drugs Product Scope
1.2 Adrenoleukodystrophy Drugs Segment by Type
1.2.1 Global Adrenoleukodystrophy Drugs Sales by Type (2020-2026)
1.2.2 Hormone Replacement
1.2.3 Transplant
1.2.4 Others
1.3 Adrenoleukodystrophy Drugs Segment by Application
1.3.1 Global Adrenoleukodystrophy Drugs Sales Comparison by Application (2020-2026)
1.3.2 Childhood Cerebral ALD
1.3.3 Adrenomyeloneuropathy (AMN)
1.3.4 Addison-only
1.3.5 Others
1.4 Adrenoleukodystrophy Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Adrenoleukodystrophy Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Adrenoleukodystrophy Drugs Price Trends (2015-2026)
2 Adrenoleukodystrophy Drugs Estimate and Forecast by Region
2.1 Global Adrenoleukodystrophy Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Adrenoleukodystrophy Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Adrenoleukodystrophy Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Adrenoleukodystrophy Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Adrenoleukodystrophy Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Adrenoleukodystrophy Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Adrenoleukodystrophy Drugs Estimates and Projections (2015-2026)
2.4.3 China Adrenoleukodystrophy Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Adrenoleukodystrophy Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Adrenoleukodystrophy Drugs Estimates and Projections (2015-2026)
2.4.6 India Adrenoleukodystrophy Drugs Estimates and Projections (2015-2026)
3 Global Adrenoleukodystrophy Drugs Competition Landscape by Players
3.1 Global Top Adrenoleukodystrophy Drugs Players by Sales (2015-2020)
3.2 Global Top Adrenoleukodystrophy Drugs Players by Revenue (2015-2020)
3.3 Global Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenoleukodystrophy Drugs as of 2019)
3.4 Global Adrenoleukodystrophy Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Adrenoleukodystrophy Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Adrenoleukodystrophy Drugs Players (Opinion Leaders)
4 Global Adrenoleukodystrophy Drugs Market Size by Type
4.1 Global Adrenoleukodystrophy Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Adrenoleukodystrophy Drugs Price by Type (2015-2020)
4.2 Global Adrenoleukodystrophy Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Adrenoleukodystrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Adrenoleukodystrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Adrenoleukodystrophy Drugs Price Forecast by Type (2021-2026)
5 Global Adrenoleukodystrophy Drugs Market Size by Application
5.1 Global Adrenoleukodystrophy Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Adrenoleukodystrophy Drugs Price by Application (2015-2020)
5.2 Global Adrenoleukodystrophy Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Adrenoleukodystrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Adrenoleukodystrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Adrenoleukodystrophy Drugs Price Forecast by Application (2021-2026)
6 United States Adrenoleukodystrophy Drugs Market Facts & Figures
6.1 United States Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
6.2 United States Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
6.3 United States Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
7 Europe Adrenoleukodystrophy Drugs Market Facts & Figures
7.1 Europe Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
7.2 Europe Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
7.3 Europe Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
8 China Adrenoleukodystrophy Drugs Market Facts & Figures
8.1 China Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
8.2 China Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
8.3 China Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
9 Japan Adrenoleukodystrophy Drugs Market Facts & Figures
9.1 Japan Adrenoleukodystrophy Drugs Sales Market Share by Company (3015-3030)
9.2 Japan Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
9.3 Japan Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
10 Southeast Asia Adrenoleukodystrophy Drugs Market Facts & Figures
10.1 Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
11 India Adrenoleukodystrophy Drugs Market Facts & Figures
11.1 India Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
11.2 India Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
11.3 India Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Adrenoleukodystrophy Drugs Business
12.1 Bluebird Bio Inc
12.1.1 Bluebird Bio Inc Corporation Information
12.1.2 Bluebird Bio Inc Business Overview
12.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Products Offered
12.1.5 Bluebird Bio Inc Recent Development
12.2 NeuroVia, Inc.
12.2.1 NeuroVia, Inc. Corporation Information
12.2.2 NeuroVia, Inc. Business Overview
12.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Products Offered
12.2.5 NeuroVia, Inc. Recent Development
12.3 Orpheris, Inc.
12.3.1 Orpheris, Inc. Corporation Information
12.3.2 Orpheris, Inc. Business Overview
12.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Products Offered
12.3.5 Orpheris, Inc. Recent Development
12.4 Minoryx
12.4.1 Minoryx Corporation Information
12.4.2 Minoryx Business Overview
12.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Minoryx Adrenoleukodystrophy Drugs Products Offered
12.4.5 Minoryx Recent Development
12.5 MedDay Pharmaceuticals
12.5.1 MedDay Pharmaceuticals Corporation Information
12.5.2 MedDay Pharmaceuticals Business Overview
12.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Products Offered
12.5.5 MedDay Pharmaceuticals Recent Development
…
13 Adrenoleukodystrophy Drugs Manufacturing Cost Analysis
13.1 Adrenoleukodystrophy Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Adrenoleukodystrophy Drugs
13.4 Adrenoleukodystrophy Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Adrenoleukodystrophy Drugs Distributors List
14.3 Adrenoleukodystrophy Drugs Customers
15 Market Dynamics
15.1 Adrenoleukodystrophy Drugs Market Trends
15.2 Adrenoleukodystrophy Drugs Opportunities and Drivers
15.3 Adrenoleukodystrophy Drugs Market Challenges
15.4 Adrenoleukodystrophy Drugs Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Adrenoleukodystrophy Drugs Sales (K Units) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Adrenoleukodystrophy Drugs Sales (K Units) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Adrenoleukodystrophy Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Adrenoleukodystrophy Drugs Sales (K Units) by Region (2015-2020)
Table 5. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2015-2020)
Table 6. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Adrenoleukodystrophy Drugs Revenue Share by Region (2015-2020)
Table 8. Global Adrenoleukodystrophy Drugs Sales (K Units) Forecast by Region (2021-2026)
Table 9. Global Adrenoleukodystrophy Drugs Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Adrenoleukodystrophy Drugs Revenue Share Forecast by Region (2021-2026)
Table 12. Global Adrenoleukodystrophy Drugs (K Units) of Key Companies (2015-2020)
Table 13. Global Adrenoleukodystrophy Drugs Sales Share by Company (2015-2020)
Table 14. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Adrenoleukodystrophy Drugs Revenue Share by Company (2015-2020)
Table 16. Global Adrenoleukodystrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenoleukodystrophy Drugs as of 2019)
Table 17. Global Adrenoleukodystrophy Drugs Average Price (US$/Unit) of Key Company (2015-2020)
Table 18. Manufacturers Adrenoleukodystrophy Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Adrenoleukodystrophy Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Adrenoleukodystrophy Drugs Players
Table 22. Global Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 23. Global Adrenoleukodystrophy Drugs Sales Share by Type (2015-2020)
Table 24. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Adrenoleukodystrophy Drugs Price (K Units) by Type (2015-2020)
Table 26. Global Adrenoleukodystrophy Drugs Sales Share by Type (2021-2026)
Table 27. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Adrenoleukodystrophy Drugs Revenue Share by Type (2021-2026)
Table 29. Global Adrenoleukodystrophy Drugs Price (K Units) by Type (2021-2026)
Table 30. Global Adrenoleukodystrophy Drugs Sales (K Units) by Application (2015-2020)
Table 31. Global Adrenoleukodystrophy Drugs Sales Share by Application (2015-2020)
Table 32. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Adrenoleukodystrophy Drugs Price (K Units) by Application (2015-2020)
Table 34. Global Adrenoleukodystrophy Drugs Sales (K Units) by Application (2021-2026)
Table 35. Global Adrenoleukodystrophy Drugs Sales Share by Application (2021-2026)
Table 36. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Adrenoleukodystrophy Drugs Revenue Share by Application (2021-2026)
Table 38. Global Adrenoleukodystrophy Drugs Price (K Units) by Application (2021-2026)
Table 39. United States Adrenoleukodystrophy Drugs Sales (K Units) by Company (2015-2020)
Table 40. United States Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
Table 41. United States Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 42. United States Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 43. United States Adrenoleukodystrophy Drugs Sales (K Units) by Application (2015-2020)
Table 44. United States Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Adrenoleukodystrophy Drugs Sales (K Units) by Company (2015-2020)
Table 46. Europe Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
Table 47. Europe Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 48. Europe Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Adrenoleukodystrophy Drugs Sales (K Units) by Application (2015-2020)
Table 50. Europe Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 51. China Adrenoleukodystrophy Drugs Sales (K Units) by Company (2015-2020)
Table 52. China Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
Table 53. China Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 54. China Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 55. China Adrenoleukodystrophy Drugs Sales (K Units) by Application (2015-2020)
Table 56. China Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
Table 57. Japan Adrenoleukodystrophy Drugs Sales (K Units) by Company (2015-2020)
Table 58. Japan Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
Table 59. Japan Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 60. Japan Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 61. Japan Adrenoleukodystrophy Drugs Sales (K Units) by Application (2015-2020)
Table 62. Japan Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Adrenoleukodystrophy Drugs Sales (K Units) by Company (2015-2020)
Table 64. Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 66. Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 68. Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
Table 69. India Adrenoleukodystrophy Drugs Sales (K Units) by Company (2015-2020)
Table 70. India Adrenoleukodystrophy Drugs Sales Market Share by Company (2015-2020)
Table 71. India Adrenoleukodystrophy Drugs Sales (K Units) by Type (2015-2020)
Table 72. India Adrenoleukodystrophy Drugs Sales Market Share by Type (2015-2020)
Table 73. India Adrenoleukodystrophy Drugs Sales (K Units) by Application (2015-2020)
Table 74. India Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
Table 75. Bluebird Bio Inc Corporation Information
Table 76. Bluebird Bio Inc Description and Business Overview
Table 77. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 78. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product
Table 79. Bluebird Bio Inc Recent Development
Table 80. NeuroVia, Inc. Corporation Information
Table 81. NeuroVia, Inc. Description and Business Overview
Table 82. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 83. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product
Table 84. NeuroVia, Inc. Recent Development
Table 85. Orpheris, Inc. Corporation Information
Table 86. Orpheris, Inc. Description and Business Overview
Table 87. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 88. Orpheris, Inc. Adrenoleukodystrophy Drugs Product
Table 89. Orpheris, Inc. Recent Development
Table 90. Minoryx Corporation Information
Table 91. Minoryx Description and Business Overview
Table 92. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 93. Minoryx Adrenoleukodystrophy Drugs Product
Table 94. Minoryx Recent Development
Table 95. MedDay Pharmaceuticals Corporation Information
Table 96. MedDay Pharmaceuticals Description and Business Overview
Table 97. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 98. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product
Table 99. MedDay Pharmaceuticals Recent Development
Table 100. Production Base and Market Concentration Rate of Raw Material
Table 101. Key Suppliers of Raw Materials
Table 102. Adrenoleukodystrophy Drugs Distributors List
Table 103. Adrenoleukodystrophy Drugs Customers List
Table 104. Adrenoleukodystrophy Drugs Market Key Trends
Table 105. Adrenoleukodystrophy Drugs Key Opportunities and Drivers
Table 106. Adrenoleukodystrophy Drugs Market Challenges
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Adrenoleukodystrophy Drugs Product Picture
Figure 2. Global Adrenoleukodystrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Adrenoleukodystrophy Drugs Market Share by Application in 2020 & 2026
Figure 6. Childhood Cerebral ALD Examples
Figure 7. Adrenomyeloneuropathy (AMN) Examples
Figure 8. Addison-only Examples
Figure 9. Others Examples
Figure 10. Global Adrenoleukodystrophy Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 11. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Adrenoleukodystrophy Drugs Price Trends Growth Rate (2015-2026) (US$/Unit)
Figure 13. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Adrenoleukodystrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Adrenoleukodystrophy Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 17. Europe Adrenoleukodystrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Adrenoleukodystrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Adrenoleukodystrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Adrenoleukodystrophy Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Adrenoleukodystrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Adrenoleukodystrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Adrenoleukodystrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Adrenoleukodystrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Adrenoleukodystrophy Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Adrenoleukodystrophy Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Adrenoleukodystrophy Drugs Players Market Share by Revenue in Adrenoleukodystrophy Drugs 2015 & 2019
Figure 28. Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Adrenoleukodystrophy Drugs Revenue Share by Type (2015-2020)
Figure 30. Global Adrenoleukodystrophy Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Adrenoleukodystrophy Drugs Revenue Share by Application (2015-2020)
Figure 32. Global Adrenoleukodystrophy Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 34. United States Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 35. Europe Adrenoleukodystrophy Drugs Sales Market Share by Company in 2019
Figure 36. Europe Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 37. Europe Adrenoleukodystrophy Drugs Sales Market Share by Application in 2019
Figure 38. China Adrenoleukodystrophy Drugs Sales Market Share by Company in 2019
Figure 39. China Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 40. China Adrenoleukodystrophy Drugs Sales Market Share by Application in 2019
Figure 41. Japan Adrenoleukodystrophy Drugs Sales Market Share by Company in 2019
Figure 42. Japan Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 43. Japan Adrenoleukodystrophy Drugs Sales Market Share by Application in 2019
Figure 44. Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Company in 2019
Figure 45. Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 46. Southeast Asia Adrenoleukodystrophy Drugs Sales Market Share by Application in 2019
Figure 47. India Adrenoleukodystrophy Drugs Sales Market Share by Company in 2019
Figure 48. India Adrenoleukodystrophy Drugs Sales Market Share by Type in 2019
Figure 49. India Adrenoleukodystrophy Drugs Sales Market Share by Application in 2019
Figure 50. Key Raw Materials Price Trend
Figure 51. Manufacturing Cost Structure of Adrenoleukodystrophy Drugs
Figure 52. Manufacturing Process Analysis of Adrenoleukodystrophy Drugs
Figure 53. Adrenoleukodystrophy Drugs Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Porter's Five Forces Analysis
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
麻酔薬・鎮痛薬の世界市場レポート2020 Market Analysis and Insights: Global Anaesthetic Drugs and Pain Drugs Market The global Anaesthetic Drugs and Pain Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Anaesthetic Drugs and Pain Drugs Scope and Market …- トレプロスチニル薬の世界市場レポート2020 Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. North America is the largest consumption place, with a consumption market share nearly 92% in 2018. Following North America, Europe are also very important market with the consumption market share of 6.8…
- 非ステロイド性抗炎症薬の世界市場レポート2020 Non-steroidal anti-inflammatory drugs refer to a class of drugs that do not contain glucocorticoids and have anti-inflammatory, antipyretic and analgesic effects. It is a first-line drug for the treatment of osteoarthritis and is widely used in other bone and joint diseases, rheumatic and immune dis…
- アルツハイマー病治療薬の世界市場レポート2020 Market Analysis and Insights: Global Alzheimer's Drugs Market The global Alzheimer's Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Alzheimer's Drugs Scope and Market Size The global Alzheimer's Drugs market is s…
- 胃不全麻痺薬の世界市場レポート2020 Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents. North America is the largest consumer of Gastroparesis Drugs in global market.The second place is Europe, following North America. Market…